From $22 Billion to $90 Billion: US Biosimilars Surge Fuels Strategic Pivot in Indian Pharma
Indian pharmaceutical companies are sharpening their biosimilars strategy as the US Food and Drug Administration’s (FDA) proposed regulatory changes open […]
